Shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) have been assigned an average rating of “Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $3.00.
A number of equities research analysts have recently commented on the stock. Maxim Group reiterated a “hold” rating on shares of Ritter Pharmaceuticals in a report on Friday, August 4th. Chardan Capital dropped their target price on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, August 8th. Finally, Zacks Investment Research cut shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th.
Shares of Ritter Pharmaceuticals (NASDAQ RTTR) remained flat at $0.35 during trading on Wednesday. The company had a trading volume of 1,389,558 shares. The stock’s market capitalization is $5.16 million. The company’s 50-day moving average is $0.44 and its 200 day moving average is $0.44. Ritter Pharmaceuticals has a 12-month low of $0.32 and a 12-month high of $3.75.
Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.14). Analysts expect that Ritter Pharmaceuticals will post ($0.42) EPS for the current fiscal year.
A hedge fund recently raised its stake in Ritter Pharmaceuticals stock. KCG Holdings Inc. increased its position in shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 105,409 shares of the biotechnology company’s stock after purchasing an additional 76,046 shares during the period. KCG Holdings Inc. owned 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent reporting period. 2.25% of the stock is owned by hedge funds and other institutional investors.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.